Statement: 1/42 patients in cohort 2 of the primary trial fainted.
Primary_evidence: Adverse Events 1:   Total: 4/42 (9.52%)   Perforation, GI 1/42 (2.38%)   Febrile neutropenia 1/42 (2.38%)   Syncope 1/42 (2.38%)   Rash/desquamation 1/42 (2.38%)